Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Ocular Adnexal Diffuse Large B-cell Lymphoma: A Multicenter International Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Munch-Petersen, HD, Rasmussen, PK, Coupland, SE, Esmaeli, B, Finger, PT, Graue, GF, Grossniklaus, HE, Honavar, SG, Khong, JJ, McKelvie, PA, Mulay, K, Prause, JU, Ralfkiaer, E, Sjö, LD, Sniegowski, MC, Vemuganti, GK & Heegaard, S 2015, 'Ocular Adnexal Diffuse Large B-cell Lymphoma: A Multicenter International Study' JAMA Ophthalmology, bind 133, nr. 2, s. 165-73. https://doi.org/10.1001/jamaophthalmol.2014.4644

APA

CBE

Munch-Petersen HD, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, Grossniklaus HE, Honavar SG, Khong JJ, McKelvie PA, Mulay K, Prause JU, Ralfkiaer E, Sjö LD, Sniegowski MC, Vemuganti GK, Heegaard S. 2015. Ocular Adnexal Diffuse Large B-cell Lymphoma: A Multicenter International Study. JAMA Ophthalmology. 133(2):165-73. https://doi.org/10.1001/jamaophthalmol.2014.4644

MLA

Vancouver

Author

Munch-Petersen, Helga D ; Rasmussen, Peter K ; Coupland, Sarah E ; Esmaeli, Bita ; Finger, Paul T ; Graue, Gerardo F ; Grossniklaus, Hans E ; Honavar, Santosh G ; Khong, Jwu Jin ; McKelvie, Penny A ; Mulay, Kaustubh ; Prause, Jan U. ; Ralfkiaer, Elisabeth ; Sjö, Lene D ; Sniegowski, Matthew C ; Vemuganti, Geeta K ; Heegaard, Steffen. / Ocular Adnexal Diffuse Large B-cell Lymphoma : A Multicenter International Study. I: JAMA Ophthalmology. 2015 ; Bind 133, Nr. 2. s. 165-73.

Bibtex

@article{0aaa981e3b5f4d3699c68789401924a5,
title = "Ocular Adnexal Diffuse Large B-cell Lymphoma: A Multicenter International Study",
abstract = "Importance: The clinical features of diffuse large B-cell lymphoma (DLBCL) subtype of ocular adnexal lymphoma have not previously been evaluated in a large cohort to our knowledge.Objective: To investigate the clinical features of ocular adnexal DLBCL (OA-DLBCL).Design, Setting, and Participants: This retrospective international cooperative study involved 6 eye cancer centers. During 30 years, 106 patients with OA-DLBCL were identified, and 6 were excluded from the study. The median follow-up period was 52 months.Main Outcomes and Measures: Overall survival, disease-specific survival (DSS), and progression-free survival were the primary end points.Results: One hundred patients with OA-DLBCL were included in the study (median age, 70 years), of whom 54 (54.0{\%}) were female. The following 3 groups of patients with lymphoma could be identified: primary OA-DLBCL (57.0{\%}), OA-DLBCL and concurrent systemic lymphoma (29.0{\%}), and ocular adnexal lymphoma relapse of previous systemic lymphoma (14.0{\%}). Of 57 patients with primary OA-DLBCL, 53 (93.0{\%}) had Ann Arbor stage IE disease, and 4 (7.0{\%}) had Ann Arbor stage IIE disease. According to the TNM staging system, 43 of 57 (75.4{\%}) had T2 tumors. Among all patients, the most frequent treatments were external beam radiation therapy with or without surgery (31.0{\%}) and rituximab-cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, prednisone (CHOP) or rituximab-CHOP-like chemotherapy with or without external beam radiation therapy (21.0{\%}). The 5-year overall survival among the entire cohort was 36.0{\%} (median, 3.5 years; 95{\%} CI, 2.5-4.5 years). Relapse occurred in 43.9{\%} (25 of 57) of patients with primary OA-DLBCL. Increasing T category of the TNM staging system was predictive of DSS (P = .04) in primary OA-DLBCL, whereas the Ann Arbor staging system was not. However, when taking all 100 patients into account, Ann Arbor stage was able to predict DSS (P = .01). Women had a longer median DSS than men (9.8 years; 95{\%} CI, 1.9-17.7 years vs 3.3 years; 95{\%} CI, 1.6-5.0; P = .03).Conclusions and Relevance: Most patients with primary OA-DLBCL were seen with Ann Arbor stage IE and TNM T2 disease. The 5-year overall survival was between 2.5 and 4.5 years, which is the 95{\%} CI around the median of 3.5 years in this cohort. Increasing T category appears to be associated with decreased DSS among patients with primary OA-DLBCL. When taking all patients into account, sex and Ann Arbor stage also seem to be DSS predictors.",
author = "Munch-Petersen, {Helga D} and Rasmussen, {Peter K} and Coupland, {Sarah E} and Bita Esmaeli and Finger, {Paul T} and Graue, {Gerardo F} and Grossniklaus, {Hans E} and Honavar, {Santosh G} and Khong, {Jwu Jin} and McKelvie, {Penny A} and Kaustubh Mulay and Prause, {Jan U.} and Elisabeth Ralfkiaer and Sj{\"o}, {Lene D} and Sniegowski, {Matthew C} and Vemuganti, {Geeta K} and Steffen Heegaard",
year = "2015",
doi = "10.1001/jamaophthalmol.2014.4644",
language = "English",
volume = "133",
pages = "165--73",
journal = "Archives of Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "2",

}

RIS

TY - JOUR

T1 - Ocular Adnexal Diffuse Large B-cell Lymphoma

T2 - A Multicenter International Study

AU - Munch-Petersen, Helga D

AU - Rasmussen, Peter K

AU - Coupland, Sarah E

AU - Esmaeli, Bita

AU - Finger, Paul T

AU - Graue, Gerardo F

AU - Grossniklaus, Hans E

AU - Honavar, Santosh G

AU - Khong, Jwu Jin

AU - McKelvie, Penny A

AU - Mulay, Kaustubh

AU - Prause, Jan U.

AU - Ralfkiaer, Elisabeth

AU - Sjö, Lene D

AU - Sniegowski, Matthew C

AU - Vemuganti, Geeta K

AU - Heegaard, Steffen

PY - 2015

Y1 - 2015

N2 - Importance: The clinical features of diffuse large B-cell lymphoma (DLBCL) subtype of ocular adnexal lymphoma have not previously been evaluated in a large cohort to our knowledge.Objective: To investigate the clinical features of ocular adnexal DLBCL (OA-DLBCL).Design, Setting, and Participants: This retrospective international cooperative study involved 6 eye cancer centers. During 30 years, 106 patients with OA-DLBCL were identified, and 6 were excluded from the study. The median follow-up period was 52 months.Main Outcomes and Measures: Overall survival, disease-specific survival (DSS), and progression-free survival were the primary end points.Results: One hundred patients with OA-DLBCL were included in the study (median age, 70 years), of whom 54 (54.0%) were female. The following 3 groups of patients with lymphoma could be identified: primary OA-DLBCL (57.0%), OA-DLBCL and concurrent systemic lymphoma (29.0%), and ocular adnexal lymphoma relapse of previous systemic lymphoma (14.0%). Of 57 patients with primary OA-DLBCL, 53 (93.0%) had Ann Arbor stage IE disease, and 4 (7.0%) had Ann Arbor stage IIE disease. According to the TNM staging system, 43 of 57 (75.4%) had T2 tumors. Among all patients, the most frequent treatments were external beam radiation therapy with or without surgery (31.0%) and rituximab-cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, prednisone (CHOP) or rituximab-CHOP-like chemotherapy with or without external beam radiation therapy (21.0%). The 5-year overall survival among the entire cohort was 36.0% (median, 3.5 years; 95% CI, 2.5-4.5 years). Relapse occurred in 43.9% (25 of 57) of patients with primary OA-DLBCL. Increasing T category of the TNM staging system was predictive of DSS (P = .04) in primary OA-DLBCL, whereas the Ann Arbor staging system was not. However, when taking all 100 patients into account, Ann Arbor stage was able to predict DSS (P = .01). Women had a longer median DSS than men (9.8 years; 95% CI, 1.9-17.7 years vs 3.3 years; 95% CI, 1.6-5.0; P = .03).Conclusions and Relevance: Most patients with primary OA-DLBCL were seen with Ann Arbor stage IE and TNM T2 disease. The 5-year overall survival was between 2.5 and 4.5 years, which is the 95% CI around the median of 3.5 years in this cohort. Increasing T category appears to be associated with decreased DSS among patients with primary OA-DLBCL. When taking all patients into account, sex and Ann Arbor stage also seem to be DSS predictors.

AB - Importance: The clinical features of diffuse large B-cell lymphoma (DLBCL) subtype of ocular adnexal lymphoma have not previously been evaluated in a large cohort to our knowledge.Objective: To investigate the clinical features of ocular adnexal DLBCL (OA-DLBCL).Design, Setting, and Participants: This retrospective international cooperative study involved 6 eye cancer centers. During 30 years, 106 patients with OA-DLBCL were identified, and 6 were excluded from the study. The median follow-up period was 52 months.Main Outcomes and Measures: Overall survival, disease-specific survival (DSS), and progression-free survival were the primary end points.Results: One hundred patients with OA-DLBCL were included in the study (median age, 70 years), of whom 54 (54.0%) were female. The following 3 groups of patients with lymphoma could be identified: primary OA-DLBCL (57.0%), OA-DLBCL and concurrent systemic lymphoma (29.0%), and ocular adnexal lymphoma relapse of previous systemic lymphoma (14.0%). Of 57 patients with primary OA-DLBCL, 53 (93.0%) had Ann Arbor stage IE disease, and 4 (7.0%) had Ann Arbor stage IIE disease. According to the TNM staging system, 43 of 57 (75.4%) had T2 tumors. Among all patients, the most frequent treatments were external beam radiation therapy with or without surgery (31.0%) and rituximab-cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, prednisone (CHOP) or rituximab-CHOP-like chemotherapy with or without external beam radiation therapy (21.0%). The 5-year overall survival among the entire cohort was 36.0% (median, 3.5 years; 95% CI, 2.5-4.5 years). Relapse occurred in 43.9% (25 of 57) of patients with primary OA-DLBCL. Increasing T category of the TNM staging system was predictive of DSS (P = .04) in primary OA-DLBCL, whereas the Ann Arbor staging system was not. However, when taking all 100 patients into account, Ann Arbor stage was able to predict DSS (P = .01). Women had a longer median DSS than men (9.8 years; 95% CI, 1.9-17.7 years vs 3.3 years; 95% CI, 1.6-5.0; P = .03).Conclusions and Relevance: Most patients with primary OA-DLBCL were seen with Ann Arbor stage IE and TNM T2 disease. The 5-year overall survival was between 2.5 and 4.5 years, which is the 95% CI around the median of 3.5 years in this cohort. Increasing T category appears to be associated with decreased DSS among patients with primary OA-DLBCL. When taking all patients into account, sex and Ann Arbor stage also seem to be DSS predictors.

U2 - 10.1001/jamaophthalmol.2014.4644

DO - 10.1001/jamaophthalmol.2014.4644

M3 - Journal article

VL - 133

SP - 165

EP - 173

JO - Archives of Ophthalmology

JF - Archives of Ophthalmology

SN - 2168-6165

IS - 2

ER -

ID: 44848315